Dysplastic Nevus Syndrome (Dysplastic Nevus)

Subscribe to Selected New Research on Dysplastic Nevus Syndrome

149 relevant articles (3 outcomes, 21 trials/studies) found for this Disease

Description: Clinically atypical nevi (usually exceeding 5 mm in diameter and having variable pigmentation and ill defined borders) with an increased risk for development of non-familial cutaneous malignant melanoma. Biopsies show melanocytic dysplasia. Nevi are clinically and histologically identical to the precursor lesions for melanoma in the B-K mole syndrome. (Stedman, 25th ed)

Also Known As:

Dysplastic Nevus; Dysplastic Nevi; Familial Atypical Multiple Mole Melanoma; B K Mole Syndrome; Nevi, Dysplastic; Syndrome, B-K Mole; Syndrome, Dysplastic Nevus; B-K Mole Syndrome; Familial Atypical Multiple Mole-Melanoma; Nevus Syndrome, Dysplastic; Nevus, Dysplastic

Relationship Network

Disease Context: Research Results

Neoplasms: 387640

Hereditary Neoplastic Syndromes: 20

Dysplastic Nevus Syndrome: 149

Neoplasms by Histologic Type: 1

Nevi and Melanomas: 26

Nevus: 1112

Dysplastic Nevus Syndrome: 149

Congenital, Hereditary, and Neonatal Diseases and Abnormalities: 422

Inborn Genetic Diseases: 549

Hereditary Neoplastic Syndromes: 20

Dysplastic Nevus Syndrome: 149

Related Diseases

1.	Melanoma (Melanoma, Malignant)
2.	Neoplasms (Cancer)
3.	Skin Diseases
4.	Keratosis
5.	Keratoacanthoma

Experts

1.	Orvos, Hajnalka: 2 articles (06/2007 - 05/2007)
2.	Dobozy, Attila: 2 articles (06/2007 - 05/2007)
3.	Hencz, Peter: 2 articles (06/2007 - 05/2007)
4.	Olah, Judit: 2 articles (06/2007 - 05/2007)
5.	Kemeny, Lajos: 2 articles (06/2007 - 05/2007)
6.	Bartusek, Dora: 2 articles (06/2007 - 05/2007)
7.	Csoma, Zsanett: 2 articles (06/2007 - 05/2007)
8.	Erdei, Zsuzsanna: 2 articles (06/2007 - 05/2007)
9.	Dosa-Racz, Eva: 2 articles (06/2007 - 05/2007)
10.	Dennery, Phyllis A: 1 article (07/2007)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Dysplastic Nevus Syndrome:

1.	Tretinoin (Retinoic Acid)FDA LinkGeneric 05/01/1994 - "CONCLUSION: These results suggest that there is concomitant clinical and histologic improvement in a significant percentage of dysplastic nevi treated with topical tretinoin" 04/01/1990 - "This study shows a definite biological effect of topical tretinoin on some dysplastic nevi." 10/01/1986 - "This experience led us to conduct the present pilot trial of topical tretinoin in dysplastic nevus syndrome" 05/01/1994 - "PATIENTS AND METHODS: Five male patients with dysplastic nevi applied tretinoin to half of the back for 6 months" 05/01/1994 - "We report the results of a pilot study of topical retinoic acid in patients with dysplastic nevi" Order ALL the reference details at left...
2.	RetinoidsIBA 08/01/1988 - "In human cancer prevention, retinoids have been most effective for skin diseases, including actinic keratosis, keratoacanthoma, epidermodysplasia verruciformis, dysplastic nevus syndrome, and basal cell carcinoma" 02/01/1989 - "To investigate the anticancer and cancer preventive effects of retinoids we have examined the effect of systemic isotretinoin on dysplastic nevi" Order ALL the reference details at left...
3.	CyanoacrylatesIBA 08/01/1989 - "Cyanoacrylate skin surface stripping: an improved approach for distinguishing dysplastic nevi from malignant melanomas." 08/01/1989 - "A cohort of 215 dysplastic nevi and malignant melanomas was studied by cyanoacrylate skin surface stripping (CSSS) and conventional histology" Order ALL the reference details at left...
4.	DNA (Deoxyribonucleic Acid)IBA 10/01/1999 - "DNA ploidy and nuclear morphometry for the classification of dysplastic nevi." 01/01/1995 - "The DNA excision repair capacity of 23 primary fibroblast lines from patients with dysplastic nevus syndrome was investigated and DNA repair synthesis ("unscheduled DNA synthesis") was determined after UV exposure" 04/01/1993 - "DNA determination in dysplastic nevi" 12/01/1990 - "Spitz and dysplastic nevi were studied by flow cytometry to search for DNA abnormality" 11/01/1993 - "Our study involved two extended familial atypical multiple mole melanoma (FAMMM) kindreds wherein a sufficient number of informative, high genetic risk, and affected patients enabled collection of pertinent tissue samples (normal skin/fibroblasts and atypical nevi/melanocytes) for cytogenetic analysis, and peripheral blood lymphocytes for DNA usage for linkage studies" Order ALL the reference details at left...
5.	AntigensIBA 02/01/1987 - "By immunoperoxidase staining, the antigen was demonstrated on a large number of melanomas and in addition on 1 of 36 nevocellular, 3 of 4 Spitz, and 5 of 14 dysplastic nevi" 10/31/1987 - "The immunohistochemical localization of melanoma-associated antigen p94 kd200 was investigated in frozen sections of 3 congenital nevi, 4 benign intradermal nevi, 1 regressing nevus, 1 blue nevus, 1 dysplastic nevus, 1 lentigo maligna, 1 superficial spreading melanoma and 2 metastatic melanomas" 04/01/1996 - "Studies of antigen expression in dysplastic nevi have been limited to some extent by difficulties in obtaining frozen nevi with which to react monoclonal antibodies" 04/01/1996 - "Tumor antigen expression in compound dysplastic nevi and superficial spreading melanoma defined by a panel of nevomelanoma monoclonal antibodies." 09/15/1989 - "No significant differences in antigen expression were found between dysplastic nevus cells and RGP melanoma, except that some antigens (nerve growth factor receptor and GD2/GD3 gangliosides) appear to be expressed at lower levels in RGP lesions, nor did VGP primary and metastatic melanomas show significant differences in antigen expression" Order ALL the reference details at left...
6.	Monoclonal AntibodiesIBA 02/01/1986 - "These human monoclonal antibodies appear to be useful in distinguishing malignant melanomas from benign nevi, with the exception of dysplastic nevi, and from basal and squamous cancers of the skin in routinely prepared tissue sections" 04/01/1996 - "Studies of antigen expression in dysplastic nevi have been limited to some extent by difficulties in obtaining frozen nevi with which to react monoclonal antibodies" 04/01/1996 - "Tumor antigen expression in compound dysplastic nevi and superficial spreading melanoma defined by a panel of nevomelanoma monoclonal antibodies." 09/01/1984 - "Using an indirect immunoperoxidase technique, 20 nevocellular nevi, 5 dysplastic nevi, 14 primary cutaneous melanomas, and 24 metastatic melanomas were tested with a panel of monoclonal antibodies to monomorphic determinants of Class I (HLA-A,B,C) and Class II (la-like) major histocompatibility complex antigens" 12/01/1992 - "Eight common nevi and 11 dysplastic nevi were evaluated for the presence of basic fibroblast growth factor, platelet-derived growth factor, transforming growth factor-alpha, interleukin-1-alpha, and interleukin-1-beta by immunohistochemical labelling with highly specific monoclonal antibodies" Order ALL the reference details at left...
7.	Proteins (Proteins, Gene)IBA 01/01/2005 - "Our current study evaluated the expression of two mismatch repair proteins, hMLH1 and hMSH2, in dysplastic nevi (DN) and cutaneous melanoma (CM)" 01/01/2005 - "Altered expression of the DNA mismatch repair proteins hMLH1 and hMSH2 in cutaneous dysplastic nevi and malignant melanoma." 02/01/2006 - "Here, we have investigated, for the first time, the expression of Notch-1, Notch-2, Jagged-1, Jagged-2 and Delta-like 1 proteins, by immunohistochemistry, in a series of benign and malignant human melanocytic lesions: five common melanocytic nevi, five 'dysplastic nevi' and 20 melanomas (five in situ, five T1-T2, five T3-T4 and five metastatic melanomas)" 01/01/1991 - "We applied a simple silver staining technique to visualize nucleolar organizer regions associated proteins (AgNORs) for the study of 47 melanocytic lesions (20 malignant melanomas, 5 dysplastic nevi, 4 Spitz nevi, 2 Reed and Gartman's fusiform nevi and 16 melanocytic nevi)" 05/01/2002 - "To remedy this issue, this article analyzes the available molecular information about dysplastic nevi and provides the current state of knowledge regarding the karyotypic abnormalities of the melanoma/dysplastic nevus trait and the involvement of allelic loss, tumor suppressor genes, mismatch repair proteins, microsatellite instability, oncogenes, extracellular matrix proteins, and growth factors in the genesis of these lesions" Order ALL the reference details at left...
8.	nucleolar organizer region associated proteinsIBA 02/01/1995 - "Stepwise increases in cellular AgNORs parallel the melanocytic progression model and thereby corroborate the intermediate nature of the dysplastic nevus" 06/01/2003 - "This study evaluated the diagnostic effectiveness of argyrophilic staining of nucleolar organizer regions (AgNORs) in separating benign nevi from MMs by assessing 27 compound nevi (CN), 20 dysplastic nevi (DN), 10 Spitz nevi (SN), and 24 MMs" 03/01/1994 - "In melanocytic nevi, dysplastic nevi and Spitz nevi, significantly less AgNORs were seen than in malignant melanomas and melanomas in situ" 02/01/1995 - "Fourteen ordinary nevi (N), seven dysplastic nevi (DN), 12 radial growth phase melanomas (RGPM), and eight vertical growth phase melanomas (VGPM) were stained for AgNORs; Ki-67 immunoreactivity was determined in paraffin sections after antigen retrieval" 01/01/1991 - "We applied a simple silver staining technique to visualize nucleolar organizer regions associated proteins (AgNORs) for the study of 47 melanocytic lesions (20 malignant melanomas, 5 dysplastic nevi, 4 Spitz nevi, 2 Reed and Gartman's fusiform nevi and 16 melanocytic nevi)" Order ALL the reference details at left...
9.	Cyclin D1IBA 06/01/2007 - "The aim of this study is to investigate cyclin D1 expression and Ki67 proliferative index in a group of melanocytic lesions to address the biologic significance of sporadic dysplastic nevi in the progression of melanocytic lesions" 02/01/2001 - "Cyclin D1 expression in dysplastic nevi: an immunohistochemical study." 06/01/2007 - "The significance of Ki-67 proliferative index and cyclin D1 expression of dysplastic nevi in the biologic spectrum of melanocytic lesions." 02/01/2001 - "CONCLUSIONS: Cyclin D1 may be involved in the pathogenesis of dysplastic nevi" 02/01/2001 - "METHODS: Cyclin D1 overexpression in 23 dysplastic nevi was detected by an immunohistochemical technique" Order ALL the reference details at left...
10.	ParaffinIBA 05/01/2001 - "Immunohistochemistry on paraffin-embedded tissue sections of 159 cases revealed a significant increase in intensity of ETB receptor expression from common nevi over dysplastic nevi and primary MM to metastatic MM. Quantitative PCR using realtime detection on 75 samples confirmed the immunohistochemical results" 03/01/2006 - "METHODS: Tissue microarray blocks were constructed with paraffin-fixed tissue of 19 nevi, 18 dysplastic nevi, 24 malignant melanomas, and 31 metastatic melanomas" 11/01/2005 - "METHODS: Paraffin-embedded sections from 12 acquired nevi, seven dysplastic nevi, 11 Spitz nevi, eight primary invasive melanomas, and three metastatic melanomas were studied for staining intensity (0-3+) and percentage of labeled cells with anti-hTERT" 01/01/1987 - "In order to gain insight into the role of macrophages in human melanoma, we studied fresh-frozen material from 15 dysplastic nevi, 199 primary melanomas, 107 melanoma metastases, and paraffin sections from 98 primary melanomas with the monoclonal antibody 25F9 which recognizes an 86 x 10(3) dalton protein present on a subset of mature human macrophages" 12/01/1990 - "The study material consisted of formalin-fixed, paraffin embedded material of 41 dysplastic nevi and 14 Spitz nevi" Order ALL the reference details at left...

Therapies and Procedures

1.	Chemoprevention 10/01/2002 - "In this article, the management of patients with dysplastic nevi and the role for dermoscopy, photographic surveillance, genetic mapping and counseling, chemoprevention, and nevi removal are discussed." 03/01/2002 - "Dysplastic nevi, a likely precursor of melanoma, are also potential targets for chemoprevention strategies" 05/01/1994 - "PURPOSE: As potential precursors of melanoma and markers of increased melanoma risk, dysplastic nevi are suitable targets of strategies for melanoma chemoprevention" 01/01/2006 - "CONCLUSIONS: The histological changes seen in a subset of treated nevi suggest a possible role for the use of topical immune response modifiers for the treatment of dysplastic nevi with the intent of melanoma chemoprevention" 01/01/2006 - "Targeting of dysplastic nevi and intermediate endpoints for melanoma chemoprevention with more intense and/or prolonged treatment regimens with imiquimod or the use of other immune response modifiers seems promising" Order ALL the reference details at left...
2.	Phototherapy (Light Therapy) 07/01/2007 - "Neonatal blue-light phototherapy could increase the risk of dysplastic nevus development." 06/01/2007 - "Neonatal blue-light phototherapy could increase the risk of dysplastic nevus development." 05/01/2007 - "Neonatal blue-light phototherapy could increase the risk of dysplastic nevus development." Order ALL the reference details at left...
3.	Semiconductor Lasers 08/01/2001 - "Histologic features seen in changing nevi after therapy with an 810 nm pulsed diode laser for hair removal in patients with dysplastic nevi." Order ALL the reference details at left...
4.	Skin Care 04/01/1985 - "Patients with dysplastic nevi should adopt sensible patterns of skin care." Order ALL the reference details at left...
5.	Heterologous Transplantation (Xenotransplantation) 04/14/2005 - "A DNA damage response was also observed in dysplastic nevi and in human skin xenografts, in which hyperplasia was induced by overexpression of growth factors" Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Dysplastic Nevus Syndrome

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 3 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>